Invo Fertility Inc 's

The company competes with local fertility clinics within a 25-mile radius based on reputation, quality of patient care, and pricing. Its INVOcell device and IVC procedure serve as alternatives to drug-only stimulation, intrauterine insemination (IUI), and conventional in vitro fertilization (IVF) methods. The fertility industry is highly competitive with established procedures, and the INVOcell device represents the first new advanced treatment incubation alternative in over forty years. Competitors in the assisted reproductive technology (ART) medical device sector include AneVivo™, developed by Anecova, and UteroPod™, developed by invoLab SA, both Swiss life sciences companies. AneVivo™ and UteroPod™ are intrauterine devices placed inside the uterus, which is considered more invasive than the INVOcell device, which is placed in the vaginal cavity. Anecova appears to be no longer active.